



## Amniotic Fluid Embolism

Click the next button to continue...



### Course Description:

Amniotic Fluid Embolism (AFE) is a high acuity, low occurring process that when recognized may be life-saving. The course will help by giving understanding of the disease and its management. AFE is a detrimental disease process that is life threatening for the women it effects. The AFE module will provide knowledge for this low occurring process.

**Approximate Time to Complete:** 40 minutes

**Revised: 5/20/2018**

***Amniotic Fluid Embolism***  
*print version*





**The purpose of this module is to improve participants understanding of amniotic fluid embolism.**

- Explain how amniotic fluid embolism can occur.
- Identify risks associated with amniotic fluid embolism syndrome.
- Recognize the signs and symptoms of amniotic fluid embolism so prompt health care delivery can be implemented.
- Initiate the initial steps of amniotic fluid embolism resuscitation with the application of equipment.
- Describe the medications used for resuscitation and how they may affect the mother and fetus.

**Objectives**



## Amniotic fluid embolism syndrome (AFES)

- *Also called anaphylactoid syndrome of pregnancy.*
- *A catastrophic condition that occurs during pregnancy or shortly after delivery [1-3].*
  
- First reported in 1926
- Not widely recognized until 1941.
- In 1941 autopsy's in a series of eight women dying from sudden shock during labor reported squamous cells and mucin of fetal origin in the maternal pulmonary vasculature [4,5].
- These same fetal squamous cells have been described in the vascular beds of maternal renals, liver, spleen, pancreas and brain [6].





- AFES is different from venous thromboembolism and is reviewed in a separate module.
- The incidence rate is between 1 - 12 cases per 100,000 deliveries in most studies [7-12].



- Several factors have been associated with AFES [7,12,13] they include:
  - precipitous or tumultuous labor
  - advanced maternal age
  - cesarean and instrumental delivery
  - placenta previa and abruption
  - grand multiparity ( $\geq 5$  live births or stillbirths)
  - cervical lacerations
  - fetal distress
  - eclampsia
  - medical induction of labor
- These factors are associated with the pathogenesis of AFES but not the direct cause.
- AFES is best considered unpreventable and unpredictable.



- The pathogenesis of AFES is thought to involve the amniotic fluid entering the maternal circulation through endocervical veins, the placental insertion site or a site of uterine trauma [14].
- Once the amniotic fluid reaches the maternal circulation it can precipitate cardiogenic shock, respiratory failure and most likely, an inflammatory and anaphylactoid response.






- Amniotic fluid has been shown to cause occlusion and vasospasm of the maternal pulmonary vasculature with animal studies, resulting in rapid development of pulmonary hypertension, acute cor pulmonale and systemic hypotension [15-17].
  - In women with AFES, invasive hemodynamic studies seem to contradict these animal studies [18,19].
- When elevated pulmonary arterial pressure, elevated pulmonary capillary wedge pressure, decreased cardiac output and decreased cardiac index are combined it suggests the principal hemodynamic alteration in humans is left ventricular failure, rather than pulmonary hypertension and right ventricular failure.



- To reconcile the human and animal observations, a biphasic pattern of cardiogenic shock in AFES has been proposed [2,15,19].
- Initial acute pulmonary hypertension and right ventricular failure (usually lasting 15-30minutes), according to the hypothesis, is followed by left ventricular dysfunction [20,21].
- Studies utilizing transesophageal echocardiography to non-invasively measure the hemodynamic parameters early during AFES report vasospasm of the pulmonary vasculature, elevated pulmonary arterial pressure and right ventricular failure, thus supporting the bi-phasic hypothesis [20,21].
- The mechanism is unclear with the later phase left ventricular failure.



- Among patients with AFES, hypoxemia is the most common manifestation of the resultant respiratory failure.
- Hypoventilation can also occur.
- The primary cause of hypoxemia involves severe ventilation/perfusion (V/Q) mismatching.

### Factors contributing to the V/Q mismatch [2] :

- Acute pulmonary hypertension during the first phase of cardiogenic shock
- Cardiogenic pulmonary edema during the second phase

### Other contributors may include [8,22] :

- Bronchospasm (about 15 percent of patients)
- Noncardiogenic pulmonary edema

- In 70% of patients who survive the first several hours, noncardiogenic pulmonary edema occurs [22].
- It generally develops as left ventricular dysfunction improves.
- Damage to the endothelial-alveolar membrane and capillary leak syndrome are evidence leading to high protein concentration in edema fluid and the presence of amniotic debris in sputum and alveolar spaces.
- Widespread damage to the alveolar-capillary membrane causes non-cardiogenic edema to occur in AFES; it usually does not produce the clinical pattern typical of acute respiratory distress syndrome (ARDS).
- Women who survive the first few hours of AFES usually recover quite rapidly, whereas the course of ARDS tends to be protracted.



- Obstruction of the pulmonary vasculature seems unlikely to be the lone cause of AFES, since there is often a lag of many hours between the entry of amniotic fluid into the the maternal circulation and onset of symptoms and signs of AFES.
- Propositions have brought up how the lag may reflect evolution of AFES of an immunologic response or inflammatory reaction to the amniotic fluid.
  - Support is evident by reports of decreased complement and increased inflammatory markers in some patients with AFES, including elevated serum trypsin levels and pulmonary mast cell activity [23-28].
  - It is hypothesized that maternal circulation allows entry of fetal antigens via the amniotic fluid.
- The clinical manifestations and the severity may be related to the degree of immunologic stimulation or the balance of arachidonic acid metabolites such as leukotrienes in the amniotic fluid [29,30].



- The symptoms and signs associated with AFES have a typical onset during labor and delivery, or immediately postpartum [2]
- In rare instances it has been reports following first or second trimester abortion, amniocentesis, or abdominal/uterine trauma and as late as 48 hours after cesarean delivery or post partum, [8,31-35].
- In review of 272 cases, most women present with rapid cardiorespiratory collapse [10].
- Preceding the onset of dyspnea and hypotension may be nonspecific symptoms such as chills, nausea, vomiting and agitation [8,10].
- Tonic-clonic seizure activity may also occur.
- A less severe presentation of AFES, partial amniotic fluid embolism syndrome, may present with only some of the major symptoms and signs [15,36,37].
  - These patients with partial amniotic fluid embolism generally present with sudden onset of milder dyspnea and hypotension.
  - In this situation, the clinical course tends to be abbreviated and the prognosis much better compared to those who have the full syndrome.



The major clinical findings are the abrupt and fulminant onset of:

Hypotension due to cardiogenic shock

Disseminated intravascular coagulation (DIC)

Hypoxemia and respiratory failure

Coma or seizures

- A prominent feature of AFES is hypotension due to cardiogenic shock.
- When AFES occurs in women, approximately 85% die from cardiogenic shock or its complications [10].
- The management of cardiogenic shock may be complicated by cardiac dysrhythmias.
  - The cardiac dysrhythmia could include pulseless electrical activity, bradycardia, ventricular fibrillation, and asystole [8].
- Management of the dysrhythmias is beyond the scope of this program.



The major clinical findings are the abrupt and fulminant onset of:

Hypotension due to cardiogenic shock

Disseminated intravascular coagulation (DIC)

Hypoxemia and respiratory failure

Coma or seizures

- A common early finding of AFES is profound hypoxemia.
  - It is the most common manifestation of respiratory failure when AFES occurs.
  - Hypoxemia is most commonly detected by pulse oximetry, but clinical findings include confusion, agitation, somnolence, dyspnea, tachycardia, tachypnea, cyanosis, and acidemia.
- Evidence may include crackles and radiographic air space disease when cardiogenic or noncardiogenic pulmonary edema is present.
- Wheezing is occasionally detected.
- Approximately half of the deaths are caused by hypoxemia and occur within the first hour of the AFE.
- Prolonged hypoxemia may lead to permanent, severe neurologic impairment or maternal brain death [8].



The major clinical findings are the abrupt and fulminant onset of:

Hypotension due to cardiogenic shock

Disseminated intravascular coagulation (DIC)

Hypoxemia and respiratory failure

Coma or seizures

- Nearly 80 percent of women with AFES develop disseminated intravascular coagulation (DIC) [1,2,8].
- DIC can begin 10-30minutes after the onset of cardiopulmonary signs and symptoms. However, DIC may also be delayed by as many as four hours [2,38-41].
- The most common manifestations of DIC are prolonged bleeding from sites of invasive interventions, such as IV sites, and bruising.
- However, in some cases, major hemorrhage may be the clinical manifestation.
- When hemorrhage occurs, it can delay the diagnosis of AFES since an exhaustive search for structural causes of hemorrhage will likely occur [42].




**AFES is diagnosed from clinical findings based on the constellation of clinical findings, rather than isolated signs and symptoms.**

- AFES should be suspected whenever shock and/or respiratory compromise develops during labor or immediately postpartum.
- Other causes of sudden intrapartum or postpartum cardiorespiratory failure must be excluded.
- Sometimes the identification of amniotic fluid debris (squamous cells, trophoblastic cells, mucin, and lanugo) from blood samples drawn from the distal port of a pulmonary artery catheter.
- Such debris is common in maternal circulation without AFES, so finding the amniotic fluid debris alone should not be considered diagnostic [43] but should involve the constellation of signs and symptoms.



- There is no specific treatment for AFES.
- The therapeutic goal is to correct hypoxemia and hypotension so that ischemic consequences (i.e. hypoxic brain injury, acute kidney injury) are prevented in the mother and adequate oxygen delivery occurs to the fetus.



- Monitoring of maternal oxyhemoglobin saturation, heart rate and rhythm, and respiratory rate should be immediately initiated in all patients with suspected AFES.
- It is important to monitor the blood pressure non-invasively at frequent intervals until continuous blood pressure monitoring is established.
- Continuous monitoring of the fetal heart rate is desirable.





## Catheters

- Following the initial assessment, plans should be made for both an arterial and a central venous catheter to be inserted.
- The initiation of therapies described below should not be delayed for catheter insertion as these procedure can be time consuming.
  - The arterial catheter can be used to continuously monitor blood pressure.
  - It also provides access to arterial blood for frequent measurement of arterial blood gases.

Slide 1 of 3





## Catheters

- The central venous catheter can be used to:
  - Infuse intravenous fluids
  - Infuse medications (i.e. vasopressors, inotropics, etc.)
  - Infuse blood products
  - Draw venous blood
- The central line can be used for limited hemodynamic monitoring by measuring the central venous pressure and the central venous oxyhemoglobin saturation.

◀ Slide 2 of 3 ▶





## Catheters

- Hemodynamic monitoring via a pulmonary arterial catheter should not be performed routinely.
- However, the central venous catheter may be helpful in selected patients [18,44,45] particularly those who have pulmonary edema, shock or uncertain intravascular volume.
- The central venous line allows invasive monitoring and helps to ensure the amount of intravenous fluid administered is enough to correct intravascular hypovolemia and optimize cardiac output, but not so much to exacerbate pulmonary edema.
- In a series of five patients with AFES who were managed with invasive hemodynamic monitoring, all five survived [18].

◀ Slide 3 of 3



- Supplemental oxygen should be provided to all patients.
- Reaching a maternal oxygen tension (PaO<sub>2</sub>) above 65mmHg is a reasonable goal.
  - To reach this goal, it often requires high flow rates of supplemental oxygen by facemask or invasive mechanical ventilation.
- When invasive mechanical ventilation can occur it provides additional options to improve oxygenation. The options include:
  - Increasing the fraction of inspired oxygen
  - Increasing the positive end-expiratory pressure
  - Prolonging or inverting the inspiratory to expiratory ratio.
- Due to the associated high risk of aspiration, non-invasive positive pressure ventilation should be avoided during pregnancy.

Slide 1 of 4 



- Factors impairing oxygen delivery to the fetus such as anemia or diminished cardiac output should be corrected.
  - This may involve red blood cell transfusions and inotropic agents.
- If the woman has delivered, these factors (i.e. anemia, diminished cardiac output) should be corrected if there is evidence of persistent hypoperfusion despite optimization of the PaO<sub>2</sub>.
- Common signs of hypoperfusion include:
  - Cool, vasoconstricted skin due to redirection of blood flow to core organs (however, warm flushed skin may be present early on in phases of sepsis)
  - Obtundation or restlessness
  - Oliguria or anuria
  - Lactic acidosis

◀ Slide 2 of 4 ▶



- Maintaining a maternal PaO<sub>2</sub> greater than 65mmHg has rationale by using women who have not delivered as an example.
- It is, however, similar for women who have delivered, but the primary concern shifts from end organ oxygen delivery to delivery of oxygen for the fetus.
- The delivery of fetal oxygen is directly related to umbilical vein oxygen tension, umbilical vein oxyhemoglobin saturation, fetal hemoglobin concentration, and maternal cardiac output.
- Healthy pregnant women have increased fetal hemoglobin concentration and maternal cardiac output. These compensate for low umbilical vein oxygen tension, so as to maintain sufficient fetal oxygen delivery.

◀ Slide 3 of 4 ▶




- The compensatory increase of fetal hemoglobin and maternal cardiac output may not be adequate to maintain the fetal oxygenation in pregnant women who have an even lower umbilical vein oxygen tension due to systemic hypoxemia.
- The level has not been determined at which the compensatory mechanisms become inadequate for the degree of maternal hypoxemia.
  - This study exposed healthy pregnant women to low fractions of inspired oxygen, a maternal PaO<sub>2</sub> below 47mmHg was associated with a decline in umbilical vein oxygen tension [46].
  - This PaO<sub>2</sub> is on the steep portion of the hemoglobin dissociation curve, where small changes in PaO<sub>2</sub> may cause large changes in oxyhemoglobin saturation and oxygen delivery.
  - It seems prudent, with this information, to maintain the maternal oxygen tension at a level that lies on the flat portion of the hemoglobin dissociation curve (i.e. >65 mmHg). This is assuming there are no complicating abnormalities in maternal cardiac output, hemoglobin or pH.

◀ Slide 4 of 4



- Hypotensive patients are treated the same with AFES regardless if they have delivered or not.
- The intravascular volume status should be immediately assessed when the woman becomes hypotensive with evaluation by history and physical exam.
- Women who are intravascularly normovolemic or hypervolemic, a vasopressor is the preferred initial therapy.
- Two reasonable approaches exist for initial therapy for those women whose intravascular volume status is uncertain.
  - First, empiric therapy can be initiated using a vasopressor.
    - This recommendation is based on the observations showing hypotension in AFES is almost always due to cardiogenic shock and coexisting intravascular hypovolemia is rare.
  - Second, the pulmonary arterial catheter can help guide hemodynamic measurements to better adjust therapy.
    - Using this approach, the intravenous fluids are titrated to optimize cardiac output and cardiac filling pressures.
    - Vasopressors are then added to achieve the desired blood pressure once the volume status is optimized.
- In the rare women who has obvious intravascular hypovolemia, a trial of intravenous fluids is reasonable.

- When vasopressor therapy is warranted, norepinephrine and dopamine are the typical drugs of first choice.
- The inotrope, dobutamine, may be added and would likely be beneficial since it increases the low cardiac output and decreases the high afterload that are characteristic of cardiogenic shock.
- However, until the vasopressors have improved blood pressure, dobutamine should not be used.
- Dobutamine, when used alone, tends to reduce blood pressure by causing a drop in the systemic vascular resistance that is out of proportion to the increase in cardiac output.



## Vasoactive Drugs

### Vasopressors



Stimulates smooth muscle contraction of the capillaries & arteries

↓  
Vasoconstriction

↘  
Rise in Mean Blood Pressure

↓  
Improved tissue perfusion and oxygenation

### Inotropes



Increase the force of contraction of myocardial muscle

↓  
Positive inotropism

↙  
Rise in Mean Blood Pressure

↓  
Improved tissue perfusion and oxygenation

- Vasopressors are used to treat hypotension in AFES even though they may diminish uteroplacental perfusion pressure.
- The rationale is found in the fact that untreated shock diminishes uteroplacental perfusion pressure and has numerous additional potential adverse consequences.
- **These include:**
  - Decreasing fetal oxygen delivery
  - Increasing the mother's risk of ischemic complications
    - Acute kidney injury
    - Hypoxic brain injury
  - Increasing mother's risk of death






- Pulmonary edema is common in AFES so a cautious approach is necessary whenever a trial of intravenous fluid is selected.
- When intravenous fluid is given, it is necessary to be administered in small boluses with recurrent assessment being required.
- The intravenous fluids should be discontinued when the intravascular volume has been replenished.
- The intravenous fluids should be promptly discontinued when new or worsening pulmonary edema occurs.
- When the pulmonary edema worsens with a trial of intravenous fluids, these women should be regarded as having uncertain intravascular volume and may be better managed with vasoactive agents.



Some women with coagulopathy or bleeding due to disseminated intravascular coagulation (DIC) may require blood product transfusion which may include the transfusion of recombinant factor VIIa.





- As discussed, AFES most commonly occurs during labor and delivery or postpartum.
- When AFES presents intrapartum, the need for immediate delivery must be determined.
- Delivery is determined mother-by-mother but factors favoring delivery include:
  - Non-reassuring fetal heart rate tracing
  - Rapid and progressive deterioration of the mother's condition
  - The opinion that delivery of the fetus may facilitate maternal resuscitative efforts
- When the cervix is fully dilated and the fetal head has descended to a station of at least +2/5, operative vaginal delivery is reasonable with a capable clinician.
- Otherwise, an emergency cesarean delivery is indicated.
- Consideration for peri-mortem cesarean may be warranted when maternal status is compromised



- Consideration for the peri-mortem cesarean is warranted when shock and cardiopulmonary resuscitative efforts fail to restore maternal circulation.
- Because brain damage begins at 5 minutes of anoxia, the procedure should be initiated at 4 minutes (the 4-minute rule) to deliver the healthiest fetus.
- If a mother has a resuscitatable cause of death, then her life may be saved as well by a prompt and timely cesarean delivery during CPR.
- Sadly, the clinicians are too often paralyzed by the horror of the maternal cardiac arrest and instinctively CPR is performed too long before turning to the peri-mortem delivery.
- This quick procedure may actually improve the situation for the mother and certainly save the child's life [48].



- However, there is significant risk of major maternal morbidity or death could when a cesarean is performed in the presence of coagulopathy.
- Some clinicians recommend that operative intervention not begin until the coagulopathy is corrected.
- Unfortunately, this is not always possible because the delay could lead to fetal death, further blood loss, and worsening of the coagulopathy.
- When a cesarean is performed, blood, fresh frozen plasma, platelets, cryoprecipitate should be available in the operating room and should be administered if there is any evidence of impaired coagulation:
  - Persistent bleeding without clotting from the incision
  - Needle site bleeding



- Case reports have described novel interventions that have been successfully used in patients with AFES:
- A right ventricular device and inhaled nitric oxide have been used in patients with right ventricular failure and pulmonary hypertension [49,50].
- In patients with severe left ventricular failure and hypoxemia the following have been utilized: cardiopulmonary bypass, intraaortic balloon pump counterpulsation and extracorporeal membrane oxygenation (ECMO) [21,51].
- The use of recombinant human factor VIIa (rVIIa) may be utilized when severe coagulopathy and bleeding, especially in those undergoing surgery to control postpartum hemorrhage occurs [50,52].
- Unfortunately, rVIIa use in AFE may be associated with thrombotic morbidity and mortality (i.e. stroke and pulmonary embolism).

### Maternal

### Neonatal

- Much more unfortunate is the fact of maternal mortality rate due to AFES has been reported between 10 to 90 percent [1,7,8,53-56], although more recent data suggest overall mortality rates may be closer to 20 percent [7,11,12].
- Even those surviving AFES generally have a poor outcome with as many as 85 percent suffer significant neurologic injury due to cerebral hypoxia [2,8].
- AFES is one of the leading causes of maternal mortality and is reported to cause ten percent of all maternal deaths in developed countries [56].




- Case reports have described novel interventions that have been successfully used in patients with AFES:
- A right ventricular device and inhaled nitric oxide have been used in patients with right ventricular failure and pulmonary hypertension [49,50].
- In patients with severe left ventricular failure and hypoxemia the following have been utilized: cardiopulmonary bypass, intraaortic balloon pump counterpulsation and extracorporeal membrane oxygenation (ECMO) [21,51].
- The use of recombinant human factor VIIa (rVIIa) may be utilized when severe coagulopathy and bleeding, especially in those undergoing surgery to control postpartum hemorrhage occurs [50,52].
- Unfortunately, rVIIa use in AFE may be associated with thrombotic morbidity and mortality (i.e. stroke and pulmonary embolism).

## Maternal

## Neonatal

- Neonatal outcomes are also poor.
- The mortality rate is estimated to be between 20 and 60 percent [8,9].
- Only 50 percent of survivors are neurologically intact.
- When the mother sustains an amniotic fluid embolism-induced cardiac arrest, overall neonatal outcomes have improved with prompt delivery of the fetus [57].





- AFES is a catastrophic condition that occurs during pregnancy or shortly after delivery.
- AFES is characterized by abrupt and fulminant onset of hypotension due to cardiogenic shock, hypoxemia, respiratory failure and DIC.
- AFES is unpredictable, unpreventable, and rare (occurring once in every 8,000 to 80,000 deliveries).
- AFES is a clinical diagnosis that is based upon the constellation of clinical findings.
- Clinicians should suspect AFES whenever shock or respiratory compromise develops during labor and delivery, or immediately postpartum.
- Other causes of sudden intrapartum or postpartum cardiorespiratory failure must be excluded.





- There is no specific treatment for AFES.
- However, the goal is to expeditiously correct hypoxemia and hypotension so that ischemic consequences such as hypoxic brain injury, acute kidney disease and myocardial injury are avoided in the mother and adequate oxygen is delivered to the fetus.
- This may require mechanical ventilation, vasopressors, inotropes, intravenous fluids, and blood products.
- Maternal mortality due to AFES remains high, although less than in previous years.
- This most likely reflects early recognition of the syndrome and appropriate aggressive therapy.
- Unfortunately, those who do survive generally have a poor outcome, most often caused by neurologic injury due to cerebral hypoxemia.
- Neonatal outcomes are also poor, although they improve with early delivery.





# Congratulations!

You have successfully completed this module.

*Click on the above 'X' to take the post-test for this course.  
If you do not attain a passing score after two attempts at  
the post-test the entire program must be repurchased.*

## References

1. Gilmore DA, Wakim J, Secrest J, Rawson R. Anaphylactoid syndrome of pregnancy: a review of the literature with latest management and outcome data. *AANA J* 2003; 71:120.
2. Gist RS, Stafford IP, Leibowitz AB, Beilin Y. Amniotic fluid embolism. *Anesth Analg* 2009; 108:1599.
3. Clark SL. Amniotic fluid embolism. *Obstet Gynecol* 2014; 123:337.
4. Meyer, JR. Embolia pulmonar amnio caseosa. *Brasil Medico* 1926; 2:301.
5. Steiner PE, Lushbaugh CC. Landmark article, Oct. 1941: Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected deaths in obstetrics. By Paul E. Steiner and C. C. Lushbaugh. *JAMA* 1986; 255:2187.
6. Liban E, Raz S. A clinicopathologic study of fourteen cases of amniotic fluid embolism. *Am J Clin Pathol* 1969; 51:477.
7. Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. *Am J Obstet Gynecol* 2008; 199:49.e1.
8. Clark SL, Hankins GD, Dudley DA, et al. Amniotic fluid embolism: analysis of the national registry. *Am J Obstet Gynecol* 1995; 172:1158.
9. Tuffnell DJ. United kingdom amniotic fluid embolism register. *BJOG* 2005; 112:1625.
10. Morgan M. Amniotic fluid embolism. *Anaesthesia* 1979; 34:20.
11. Kramer MS, Rouleau J, Baskett TF, et al. Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. *Lancet* 2006; 368:1444.

## References

12. Knight M, Tuffnell D, Brocklehurst P, et al. Incidence and risk factors for amniotic-fluid embolism. *Obstet Gynecol* 2010; 115:910.
13. Turner LA, Kramer MS, Liu S, Maternal Mortality and Morbidity Study Group of the Canadian Perinatal Surveillance System. Cause-specific mortality during and after pregnancy and the definition of maternal death. *Chronic Dis Can* 2002; 23:31.
14. Courtney LD. Amniotic fluid embolism. *Obstet Gynecol Surv* 1974; 29:169
15. Clark SL. New concepts of amniotic fluid embolism: a review. *Obstet Gynecol Surv* 1990; 45:360.
16. ATTWOOD HD, DOWNING ES. EXPERIMENTAL AMNIOTIC FLUID AND MECONIUM EMBOLISM. *Surg Gynecol Obstet* 1965; 120:255.
17. Reis RL, Pierce WS, Behrendt DM. Hemodynamic effects of amniotic fluid embolism. *Surg Gynecol Obstet* 1969; 129:45.
18. Clark SL, Cotton DB, Gonik B, et al. Central hemodynamic alterations in amniotic fluid embolism. *Am J Obstet Gynecol* 1988; 158:1124.
19. Clark SL, Montz FJ, Phelan JP. Hemodynamic alterations associated with amniotic fluid embolism: a reappraisal. *Am J Obstet Gynecol* 1985; 151:617.
20. Shechtman M, Ziser A, Markovits R, Rozenberg B. Amniotic fluid embolism: early findings of transesophageal echocardiography. *Anesth Analg* 1999; 89:1456.
21. Stanten RD, Iverson LI, Daugharty TM, et al. Amniotic fluid embolism causing catastrophic pulmonary vasoconstriction: diagnosis by transesophageal echocardiogram and treatment by cardiopulmonary bypass. *Obstet Gynecol* 2003; 102:496.

## References

22. Price TM, Baker VV, Cefalo RC. Amniotic fluid embolism. Three case reports with a review of the literature. *Obstet Gynecol Surv* 1985; 40:462.
23. Nishio H, Matsui K, Miyazaki T, et al. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. *Forensic Sci Int* 2002; 126:53.
24. Farrar SC, Gherman RB. Serum tryptase analysis in a woman with amniotic fluid embolism. A case report. *J Reprod Med* 2001; 46:926.
25. Benson MD, Kobayashi H, Silver RK, et al. Immunologic studies in presumed amniotic fluid embolism. *Obstet Gynecol* 2001; 97:510.
26. Fineschi V, Gambassi R, Gherardi M, Turillazzi E. The diagnosis of amniotic fluid embolism: an immunohistochemical study for the quantification of pulmonary mast cell tryptase. *Int J Legal Med* 1998; 111:238.
27. Benson MD. A hypothesis regarding complement activation and amniotic fluid embolism. *Med Hypotheses* 2007; 68:1019.
28. Benson MD. Current concepts of immunology and diagnosis in amniotic fluid embolism. *Clin Dev Immunol* 2012; 2012:946576.
29. Azegami M, Mori N. Amniotic fluid embolism and leukotrienes. *Am J Obstet Gynecol* 1986; 155:1119.
30. Benson MD. Nonfatal amniotic fluid embolism. Three possible cases and a new clinical definition. *Arch Fam Med* 1993; 2:989.
31. Lawson HW, Atrash HK, Franks AL. Fatal pulmonary embolism during legal induced abortion in the United States from 1972 to 1985. *Am J Obstet Gynecol* 1990; 162:986.

## References

32. Hasaart TH, Essed GG. Amniotic fluid embolism after transabdominal amniocentesis. *Eur J Obstet Gynecol Reprod Biol* 1983; 16:25.
33. Mainprize TC, Maltby JR. Amniotic fluid embolism: a report of four probable cases. *Can Anaesth Soc J* 1986; 33:382.
34. Ellingsen CL, Eggebø TM, Lexow K. Amniotic fluid embolism after blunt abdominal trauma. *Resuscitation* 2007; 75:180.
35. Rainio J, Penttilä A. Amniotic fluid embolism as cause of death in a car accident—a case report. *Forensic Sci Int* 2003; 137:231.
36. Masson RG, Ruggieri J, Siddiqui MM. Amniotic fluid embolism: definitive diagnosis in a survivor. *Am Rev Respir Dis* 1979; 120:187.
37. Wasser WG, Tessler S, Kamath CP, Sackin AJ. Nonfatal amniotic fluid embolism: a case report of post-partum respiratory distress with histopathologic studies. *Mt Sinai J Med* 1979; 46:388.
38. Peterson EP, Taylor HB. Amniotic fluid embolism. An analysis of 40 cases. *Obstet Gynecol* 1970; 35:787.
39. Beller FK. Disseminated intravascular coagulation and consumption coagulopathy in obstetrics. *Obstet Gynecol Annu* 1974; 3:267.
40. Bastien JL, Graves JR, Bailey S. Atypical presentation of amniotic fluid embolism. *Anesth Analg* 1998; 87:124.
41. Malhotra P, Agarwal R, Awasthi A, et al. Delayed presentation of amniotic fluid embolism: lessons from a case diagnosed at autopsy. *Respirology* 2007; 12:148.
42. Davies S. Amniotic fluid embolism and isolated disseminated intravascular coagulation. *Can J Anaesth* 1999; 46:456.

## References

43. Lee W, Ginsburg KA, Cotton DB, Kaufman RH. Squamous and trophoblastic cells in the maternal pulmonary circulation identified by invasive hemodynamic monitoring during the peripartum period. *Am J Obstet Gynecol* 1986; 155:999.
44. Clark SL. Amniotic fluid embolism. *Crit Care Clin* 1991; 7:877.
45. Vanmaele L, Noppen M, Vincken W, et al. Transient left heart failure in amniotic fluid embolism. *Intensive Care Med* 1990; 16:269.
46. Wulf KH, Kunzel W, Lehman V. Clinical aspects of placental gas exchange. In: *Respiratory gas exchange and blood flow in the placenta*, Longo LD, Bartels H (Eds), United States Public Health Service, Bethesda, MD 1972. p.505.
47. Vasoactive Drugs, Image:  
<https://www.google.com/search?q=respiratory+failure&biw=835&bih=655&source=lnms&tbm=isch&sa=X&sqi=2&ved=0ahUKEwinqLWNy>
48. Katz, Vern L, MD; Perimortem Cesarean Delivery: Its Role in Maternal Mortality; *Seminars in Perinatology*, Volume 36, Issue 1, February 2012, Pages 68–72
49. McDonnell NJ, Chan BO, Frengley RW. Rapid reversal of critical haemodynamic compromise with nitric oxide in a parturient with amniotic fluid embolism. *Int J Obstet Anesth* 2007; 16:269.
50. Nagarsheth NP, Pinney S, Bassily-Marcus A, et al. Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism. *Anesth Analg* 2008; 107:962.
51. Hsieh YY, Chang CC, Li PC, et al. Successful application of extracorporeal membrane oxygenation and intra-aortic balloon counterpulsation as lifesaving therapy for a patient with amniotic fluid embolism. *Am J Obstet Gynecol* 2000; 183:496.

## References

52. Leighton BL, Wall MH, Lockhart EM, et al. Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports. *Anesthesiology* 2011; 115:1201.
53. Gilbert WM, Danielsen B. Amniotic fluid embolism: decreased mortality in a population-based study. *Obstet Gynecol* 1999; 93:973.
54. Clark SL. Amniotic fluid embolism. *Clin Perinatol* 1986; 13:801.
55. Suidan JS. Amniotic fluid embolism. *Middle East J Anesthesiol* 1989; 10:279.
56. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. *Obstet Gynecol* 2010; 116:1302.
57. Clark SL. Amniotic fluid embolism. *Clin Obstet Gynecol* 2010; 53:322.